MRgLITT for mTLE: A PROBE Trial

Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Mesial Temporal Lobe Epilepsy: A Prospective, Randomized, Open Blinded, End-point Trial

How does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?

1. Compare the clinical prognosis between magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) and traditional open surgery (OS) on patients with mesial temporal lobe epilepsy (mTLE).
2. Explore the factors associated with seizure outcomes.

Inclusion Criteria:

• 18-65 years.
• Drug-resistant mesial temporal lobe epilepsy.
• Seizure frequency ≥ 1 time /month.
• Participants approved.

Exclusion Criteria:

• History of brain surgery.
• Intracranial space occupying lesions.
• Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections.